Preoperative/neoadjuvant medical therapy for early breast cancer

Lancet Oncology

Volumn 2, Issue 9, 2001, Pages 561-570

  Smith, Ian E ^a   Lipton, Lara ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SURVIVAL RATE; TUMOR RECURRENCE;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0035468731     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00490-9     Document Type: Review

References (49)

1. DeLena M., Zucali R., Viganotti G., et al. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-4) breast cancer. Cancer Chemother Pharmacol. 1:1978;53-61.
2. Hortobagyi G.N., Blumenschein G.R., Spanos W., et al. Multimodal treatment of locally advanced breast cancer. Cancer. 51:1983;763-769.
3. Haagensen DC, Bodian C. A personal experience with Halsted's radical mastectomy. Ann Surg 1984; 143-150.
4. Forrest A.P., Levack P.A., Chetty U., et al. A human tumour model. Lancet. 2:1986;840-842.
5. Mauriac L., Durand M., Avril A., et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm: results of a randomized trial in a single centre. Ann Oncol. 2:1991;347-354.
6. Mauriac L., MacGrogan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomised trial with a 124-month follow-up. Ann Oncol. 10:1999;47-52.
7. Scholl S.M., Fourquet A., Asselain J.Y., et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer. 30A:1994;645-652.
8. Broet P., Scholl S.M., de la Rochefordiere A., et al. Short and long-term effects of survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat. 58:1999;151-156.
9. Semiglazov V.F., Topuzov E.E., Bavli J.L., et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 5:1994;591-595.
10. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 16:1998;2672-2685.
11. Powles T.J., Hickish T.F., Makris A., et al. Randomised trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 13:1995;547-552.
12. Makris A., Powles T.J., Ashley S.E., et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 9:1998;1179-1184.
13. Smith I.E., Walsh G., Jones A., et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 13:1995;424-429.
14. Bonadonna G., Valagussa P., Brambilla C., et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 16:1998;93-100.
15. Ellis P., Smith I., Ashley S., et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol. 16:1998;107-114.
16. Smith I.E., Jones A.L., O'Brien M.E.R., et al. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer. 29A:1993;1796-1799.
17. Cameron D.A., Anderson E.D.C., Levack P., et al. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. Br J Cancer. 76:1997;1099-1105.
18. Buzdar A.U., Singletary S.E., Theriault R.L., et al. Prospective evaluation of paclitaxel versus combination chemotherapy with flurouracil, Adriamycin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 17:1999;3412-3417.
19. Moliterni A., Tagliabue E., Tarenzi G., et al. Non-randomised comparison between primary chemotherapy (PC) with single agent anthracycline or doxorubicin + paclitaxel (AT). Proc Am Soc Clin Oncol. 19:2000;357.
20. Amat S., Bougnoux P., Penault-Llorca F., et al. Primary chemotherapy for operable breast cancer: High pathological response rate induced by docetaxel. Proc Am Soc Clin Oncol. 19:2000;500.
21. Hutcheon A.W., Ogston K.N., Heys S.D., et al. Primary chemotherapy in the treatment of breast cancer: significantly enhanced clinical and pathological responses with docetaxel. Proc Am Soc Clin Oncol. 19:2000;317.
22. Jacquillat C., Weil M., Baillet F., et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 66:1990;119-127.
23. Smith I.E., A'Hern R.P., Howell A., et al. Preoperative continuous infusional ECisF (epirubicin, cisplatin and infusional 5FU) vs. conventional AC chemotherapy for early breast cancer: a phase III multicentre randomised trial by the TOPIC Group. Proc Am Soc Clin Oncol. 19:2000;320.
24. Luporsi E., Vanlemmens L., Coudert F., et al. Six cycles of FEC 100 vs epirubicin-docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: preliminary results of a randomised phase II trial of GIREC S01. Proc Am Soc Clin Oncol. 19:2000;355.
25. Hortobagyi G.N., Ames F.C., Buzdar A.U., et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 62:1988;2507-2516.
26. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 17:1999;460-469.
27. Verrill M.W., Ashley S.E., Walsh G.A., et al. Pathological complete response (pCR) in patients treated with neoadjuvant chemotherapy for operable breast cancer. Breast Cancer Res Treat. 50:1998;328.
28. Pierga J.-Y., Mouret E., Dieras V., et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer. 83:2000;1480-1487.
29. Frye D., Buzdar A., Hortobagyi G. Prognostic significance of axillary nodal involvement after preoperative chemotherapy in stage III breast cancer. (abstr 81). Proc Am Soc Clin Oncol. 14:1995;95.
30. Ellis P.A., Smith I.E., McCarthy K., et al. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet. 349:1997;849.
31. Shao Z.-M., Li J., Wu J., et al. Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis. Breast Cancer Res Treat. 53:1999;263-269.
32. Billgren A.M., Rutqvist L.E., Tani E., et al. Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol. 38:1999;597-601.
33. Makris A., Powles T.J., Dowsett M., et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 3:1997;593-600.
34. Chang J., Powles T.J., Allred D.C., et al. Predictive molecular markers for clinical outcome following primary chemotherapy for operable breast cancer. Proc Am Soc Clin Oncol. 17:1998;384.
35. Gregory R.K., Powles T.J., Salter J., et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine trial. Breast Cancer Res Treat. 59:2000;171-175.
36. Petit T., Ghnassia J., Rodier J., et al. Relationship between erbB-2 status and neoadjuvant chemotherapy response is dependent on anthracycline dose intensity. Proc Am Soc Clin Oncol. 19:2000;96a.
37. Preece P.E., Wood R.A.B., Mackie C.R., et al. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. BMJ. 284:1982;869-870.
38. Gazet J.-C., Markopoulos C.H., Ford H.T., et al. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 2:1988;679-681.
39. Robertson J.F.R., Todd J.H., Ellis I.O., et al. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ. 297:1988;511-514.
40. Bates T., Riley D.L., Houghton J., et al. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg. 78:1991;591-594.
41. Mansi J.L., Smith I.E., Walsh G., et al. Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol. 25:1989;1623-1627.
42. Anderson E.D., Forrest A.P., Hawkins R.A., et al. Primary systemic therapy for operable breast cancer. Br J Cancer. 63:1991;561-566.
43. Hoff P.M., Valero V., Buzdar A.U., et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer. 88:2000;2054-2060.
44. Bonneterre J., Thürlimann B., Robertson J.F.A., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol. 18:2000;3748-3757.
45. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol. 18:2000;3758-3767.
46. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 19:2001;2596-2606. updated? include/delete.
47. Dixon J.M., Renshaw L., Bellamy C., et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res. 6:2000;2229-2235.
48. Miller W.R., Anderson T.J., Hawkins R.A., et al. Neoadjuvant endocrine treatment: the Edinburgh experience. Dowsett M., Howell A. Primary medical therapy for breast cancer: clinical and biological aspects. 1999;89-99 Elsevier, Amsterdam.
49. Ellis M.J., Jaenicke F., Llombart-Cussac A., et al. A randomized double-blind multicenter study of preoperative tamoxifen versus Femara™ (letrozole) for postmenopausal women with ER and/or PgR positive breast cancer ineligible for breast-conserving surgery. Correlation of clinical response with tumor gene expression and proliferation (abstr). Breast Cancer Res Treat. 64:2000;29.